Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex

NCT02876081 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped medical decision

Conditions

SMALL CELL LUNG CARCINOMA

Interventions

DRUG: Afatinib

Sponsor

Fondation Hôpital Saint-Joseph